Cargando…

Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance

The predictive factors of long-term clinical benefits in patients with hepatitis C virus (HCV)—related liver cirrhosis after Direct Antiviral Agents (DAA) treatment are still undefined. The aim of this study was to identify any predictors of liver failure, hepatocellular carcinoma (HCC) and/or death...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franzè, Maria Stella, Filomia, Roberto, Caccamo, Gaia, Pitrone, Concetta, Alibrandi, Angela, Saitta, Carlo, Caspanello, Amalia Rita, Asero, Clelia, Arcadi, Vittoria, Raimondo, Giovanni, Cacciola, Irene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699534/ https://www.ncbi.nlm.nih.gov/pubmed/36579534 http://dx.doi.org/10.3390/jpm12111794

Ejemplares similares

Over time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
por: Cacciola, Irene, et al.
Publicado: (2021)

Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography
por: Filomia, Roberto, et al.
Publicado: (2016)

High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease
por: Asero, Clelia, et al.
Publicado: (2023)

EXPERIMENTAL HYPERGAMMAGLOBULINEMIA IN MINK
por: Henson, James B., et al.
Publicado: (1962)

Hypergammaglobulinemia in the pediatric population
por: Lo, Mindy S, et al.
Publicado: (2012)

Occult HBV infection
por: Raimondo, Giovanni, et al.
Publicado: (2012)

Lymphocytosis, Lymphocytopenia, Hypergammaglobulinemia, and Hypogammaglobulinemia
por: Mims, Martha P.
Publicado: (2018)

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy
por: Leuştean, Anca, et al.
Publicado: (2021)

Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia
por: Zack, Marie-Therese, et al.
Publicado: (2022)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
por: Morisco, Filomena, et al.
Publicado: (2021)

PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients
por: Saitta, Carlo, et al.
Publicado: (2017)

Diagnostic Challenge in a Patient Presenting with Ascites and Hypergammaglobulinemia
por: Mustika, Syifa, et al.
Publicado: (2021)

Liver transplantation reverses hypergammaglobulinemia in patients with chronic hepatic failure
por: Lebherz-Eichinger, Diana, et al.
Publicado: (2015)

Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis
por: Taubert, Richard, et al.
Publicado: (2017)

The Acute Onset of Autoimmune Hepatitis During Pregnancy in the Absence of Hypergammaglobulinemia and Autoantibodies
por: Kawada, Ai, et al.
Publicado: (2021)

Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort
por: Calvaruso, Vincenza, et al.
Publicado: (2021)

Induction of Hypergammaglobulinemia and Autoantibodies by Salmonella Infection in MyD88-Deficient Mice
por: Issac, Jincy M., et al.
Publicado: (2018)

A Case of Immunoglobulin G4–Related Autoimmune Pancreatitis With Extreme Hypergammaglobulinemia
por: Huo, Lanqing, et al.
Publicado: (2020)

Continuous hypergammaglobulinemia and proteinuria after the recovery of the visceral Leishmaniasis: a case report
por: Zou, Linfeng, et al.
Publicado: (2021)

Case Report: Atrial Fibrillation After Intravenous Administration of Iodinated Contrast Medium in a Patient With Hepatocellular Carcinoma
por: Maimone, Sergio, et al.
Publicado: (2015)

Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes
por: Licata, Anna, et al.
Publicado: (2023)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
por: Marino, Andrea, et al.
Publicado: (2021)

Interleukin 6 production in experimental cerebral malaria: modulation by anticytokine antibodies and possible role in hypergammaglobulinemia
Publicado: (1990)

Hypergammaglobulinemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study
por: Lo, Mindy S, et al.
Publicado: (2013)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Effects of Late Evening Snack on Cirrhotic Patients: A Systematic Review and Meta-Analysis
por: Guo, Ying-jie, et al.
Publicado: (2018)

Effects of late evening snacks on glucose homeostasis in cirrhotic patients: A meta-analysis
por: Chen, Ni, et al.
Publicado: (2023)

Serum Levels of IL-33 and Correlation with IL-4, IL-17A, and Hypergammaglobulinemia in Patients with Autoimmune Hepatitis
por: Liang, Ma, et al.
Publicado: (2018)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs
por: Ponnuvel, Suresh, et al.
Publicado: (2023)

Maternal and Neonatal Outcomes in Intrahepatic Cholestasis of Pregnancy
por: Granese, Roberta, et al.
Publicado: (2023)

Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis
por: Ho, Cheng-Hsun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7e9ogokcfsfcol41d1ikihlmds